TandemAI Secures $22M Series A Extension to Boost AI‑Driven Drug Discovery

Why It Matters

The infusion of $22 million highlights strong market confidence in AI‑powered drug discovery, potentially speeding up candidate identification and giving TandemAI a competitive edge in a rapidly evolving biotech landscape.

Deal Summary

TandemAI, a New York‑based drug discovery firm, announced a $22 million Series A extension round. The funding, led by KHK Fund and V‑Capital among other investors, will be used to expand operations and accelerate R&D on its AI‑powered SaaS platform.